迷迷糊糊的疱疹系列研究----先从感叹开始 [复制链接]

Agenus“疱疹的研究在生物技术国际会议主办结果显示强烈的免疫反应

小说，多价，HSV - 2治疗性疫苗产生的CD4 +和CD8 +免疫应答


列克星敦，马萨诸塞州，2011年6月27日（通过COMTEX商业电讯） - Agenus公司/ quotes/zigman/2380056/quotes/nls/agen AGEN -3.67％，是治疗癌症和传染病的治疗性疫苗的领先开发商，今天宣布从第一阶段的治疗生殖器疱疹的HerpV我的研究，结果将提交由大卫Koelle博士，医学教授，在过敏和在华盛顿大学医学院的传染病科，在BIO国际公约华盛顿特区。该数据将在上午10:00至11:30会议题为“治疗和预防为HSV - 2感染的治疗方法。”周二，6月28日

HerpV是一种研究性治疗性疫苗正在研制治疗单纯疱疹病毒2型（HSV - 2），病毒感染引起的生殖器疱疹患者。
从第一阶段HerpV试验结果表明，候选疫苗引发的细胞免疫反应，刺激CD4 +和CD8 + T细胞。一个完整的数据集上的稿件已经被提交给同行评审的期刊。

“我相信这些数据代表了他们的一种治疗生殖器疱疹在人类第一次发现。呈现出疱疹的治疗性疫苗引出的CD4 +和CD8 +在人类T细胞的反应是空前的，”Koelle说。 “我们非常鼓舞，这些结果为研究数据表明，免疫反应的这些武器都需要为生殖器疱疹的治疗成功的业务。”

他说：“如HerpV治疗性疫苗候选利用潜力的爆发，并最终在管理与生殖器疱疹患者的疾病传播的是，补充说：”Koelle。 “能够影响和可能减少生殖器疱疹的传播将是遏制这一流行病影响的六个美国成人中就有一个巨大的一步。”
“HerpV代表了我们第一个证明了概念为热休克蛋白在感染性疾病领域的重组系列平台的应用研究，我们可能会使用我们的重组创造HSP技术平台多种传染病的治疗性疫苗”，表示加罗阿尔缅，博士，董事长兼首席执行官Agenus。 “该公司目前正在探索二期HerpV发展道路。”

HerpV研究结果

在这个四臂，第一阶段的研究，35 HSV - 2血清阳性患者接受HerpV（在研究中被指定为AG - 707加QS - 21），AG - 707，QS - 21单独或安慰剂。患者接受为期两个星期的时间间隔三种治疗方法。这种疫苗耐受性良好，注射部位疼痛为最常见的不良事件。
所有患者谁属的免疫反应可评估，并获得HerpV呈显着性CD4 + T细胞的反应（100％，7 / 7）对HSV - 2经IFNγELISPOT检测抗原，这些患者多数表现出了CD8 + T细胞反应（75％，6 /。

这项研究是首次证明热休克蛋白复合物对病毒抗原诱导抗原特异性T细胞在人体的反应。

关于疱疹

据美国疾病控制中心，生殖器疱疹影响​​超过6000万美国人 - 用一个额外的150万每year.1这种疾病通常在每年6暴发结果的新案例 - 或在6至14岁和49人1 ，但在严重的情况下更多的发作可能result.2生殖器疱疹的心理后果是相当显着，高达57％的感染者表示，他们曾与疱疹性关系的干扰，50％的人觉得很难忍受生殖器疱疹， 37％认为，疱疹已经毁了他们的lives.3此外，正在进行的研究表明越来越抵抗现有的治疗生殖器疱疹。

关于HerpV

HerpV是为生殖器疱疹，这是由单纯疱疹病毒2型（HSV - 2）引起的治疗重组（现成的，现成的）治疗性疫苗。这种疫苗是基于Agenus“热休克蛋白（HSP）的平台技术，并包含Agenus专有佐剂QS - 21 Stimulon（R）佐剂。热休克蛋白，也称为应激蛋白，在所有细胞（正常细胞，肿瘤细胞和感染细胞）和最近的研究发现表明，热休克蛋白参与了蛋白质片段（或多肽）在细胞表面呈现一个重要的角色，帮助免疫系统识别病变细胞。虽然在发展的初期重点在HSV - 2以来，联保技术平台有可能被用于现成的，现成的，如人乳头状瘤病毒，艾滋病毒，肝炎，疟疾和肺结核治疗多种感染性疾病。

HerpV包括重组人热休克蛋白70与32种不同的35个碱基由HSV - 2蛋白质合成肽复合物。这种疱疹抗原谱广，是为了让更准确的定位和免疫监视，降低了免疫逃逸的可能性。此外，在HerpV抗原多样性增加提供了广泛的患者群细分疗效的机会。

关于QS - 21

QS - 21是一种疫苗佐剂旨在加强人体的免疫反应的疫苗的抗原，从而使之更有效。 QS - 21已成为研究性的跨多种传染病的预防疫苗制剂发展的重要组成部分，似乎是用于治疗癌症和退化性疾病的几个研究性治疗性疫苗至关重要。目前，QS - 21目前正在研究在临床试验中约15疫苗的迹象，其中四个阶段的3所Agenus“持牌人，其中包括葛兰素史克和扬森免疫治疗阿尔茨海默氏症，是强生公司的全资子公司的研究。

关于Agenus

Agenus公司是一家生物技术公司合作开发用于治疗癌症和传染病。该公司致力于推进与多个产品通过门诊，包括一些产品已进入后期临床试验，通过先进的企业合作伙伴的候选人人选强大的平台技术为基础的免疫治疗产品。欲了解更多信息，请访问www.agenusbio.com。

该Agenus标志可用在http://www.globenewswire.com/newsroom/prs/?pkgid=8187

前瞻性声明

本新闻稿包含包括有关临床试验活动，数据显示，与本公司产品的候选人在预防和治疗疾病的潜在应用前瞻性陈述。这些前瞻性陈述会受到风险和不确定性可能导致实际结果大不相同。这些风险和不确定因素包括，除其他因素下，我们对风险因素的季度报告表格10 - Q与证券交易委员会提交了截至2011年3月31日的期限一节所述。 Agenus告诫投资者不要对本新闻稿中的前瞻性陈述相当大的依赖。这些声明仅截至本文件日期，并Agenus没有义务更新或修改的声明。所有前瞻性陈述都明确限定在本警示性声明。 Agenus“业务受重大风险和不确定因素，包括上述确定的。当评估Agenus的业务和证券，投资者应慎重考虑这些风险和不确定性。
朗读
显示对应的拉丁字符的拼音字典“Google 翻译”适合以下用途：搜索手机聊天商务关于 Google 翻译关闭即时翻译隐私权政策帮助
©2011商务工具译者工具包关于 Google 翻译博客隐私权政策帮助►

看样子这次会议没有什么太好的消息，悲哀啊

最近比较忙，工作和生活都比较忙，有段时间没来论坛了，大家和迷惑姐姐都还好吧？

瑞典公司显然已完成三期临床试验... ... Thread Tools 主题工具 Show Printable Version 显示可打印版本 Email this Page… 电邮这页... Subscribe to this Thread… 订阅此主题... Today 01:00 PM #1 今天01:00 PM ＃1 Hitwithabrick Hitwithabrick  View Profile 查看资料  View Forum Posts 查看论坛帖子  
HC Member

慧聪会员


Join Date注册日期 Jun 2011 2011年6月
Posts帖子 2 2  Swedish company apparently completed Phase III clinical Trials...瑞典公司显然已完成三期临床试验... ...
Good morning,早上好，

I am new to this board, but not new to Herpes..having been positive for a year and a half.我是新来这个论坛，但不是新的疱疹..已被一年半阳性。

The other night I was researching information on vaccines, and came across an article about a swedish pharmaceutical company which had completed Phase III clinical trials on a vaccine...they were compiling the results and had said they would release the results August 28, 2011.另一个晚上，我正在研究的疫苗的信息，并遇到一个关于瑞典的制药公司，已完成了疫苗的三期临床试验的文章... ...他们编制的结果，并表示，他们将释放的结果2011年8月28日。 I had to close the page fast, but had intended to save it.我不得不关闭网页速度快，但原本打算将其保存。 Now after 3 days of extensive searching I can't find it.现在，经过3天的广泛搜索，我找不到它。

I had hoped to post the link...but figure the rest of the board might be interested in finding it too and posting it.我曾希望张贴连结...但数字电路板的其余部分可能是在寻找它也和张贴有兴趣。

I got to it through another site and had to translate the page.我得到了它，并通过其他网站的页面翻译。

I have a feeling the race is on for a vaccine...the companies know its coming and the first one to get it out will make the money.我有一种感觉，在比赛上的疫苗是... ...公司知道它的未来和第一个得到它将使钱。

感谢上面的战友关于转帖瑞典疫苗的文章。 这是去年三月公布的消息， 说是试验接近尾声， 但是人体试验结果没有出来， 希望今年八月能够出结果。  

不过已经经过研究发现疱疹与老年痴呆症有密切联系。  所以我们大家一定要在年老到来之前把疱疹消灭掉。  

加油，  

迷糊1


Swedish lab offers hope on genital herpes vaccine
Published: 17 Mar 10 10:33 CET | Double click on a word to get a translation
Online: http://www.thelocal.se/25574/20100317/

Share119  Researchers in Gothenburg have developed a promising new vaccine against genital herpes, with successful tests on mice offering hope of an STD-free future for millions, Gothenburg daily Göteborgs-Posten reports.


•Swedish team turns skin into nerve cells (7 Jun 11)
•Swedish scientists help people 'feel like Barbie' (27 May 11)
•Surgery better for tackling prostate cancer: Swedish study (6 May 11)
The vaccine, which uses a protein produced by the type 2 herpes virus together with a substance which stimulates the immune system, has been developed by researchers at the Sahlgrenska Academy in Gothenburg.

The research team vaccinated a sample of mice and were able to trace the infection - the first time this has been achieved with the herpes virus. The study found that somewhere between the mucous membrane and the spinal ganglion the infection lost its virility.

"We found the genome of the virus in the spinal cord, but no viable virus particles. We do not know where on the path from the mucous membrane to the nerve cell that it has lost its ability to cause disease," said Staffan Görander at the Sahlgrenska Academy to the newspaper.

It is hoped that further research will enable the new vaccine to provide protection against the most common form of genital herpes which is caused by the herpes simplex virus, with type 2 being the most common.

Around 500 million people are infected with genital herpes, which is transferred sexually and substantially increases the risk of being infected with HIV. There is currently no vaccine against the disease.


Peter Vinthagen Simpson
news@thelocal.se
+46 8 656 6518
What do you think? Leave your comment below.

这次会议还是有成果的， 这个  vical 公司就是致力于1二型的疫苗抑制。  目前全世界50岁的活跃性人口中， 没四人有一个人有二型疱疹， 全世界五亿人有， 美国的五千万疱疹二型人口， 只有五十万人有明显的疱疹疾病症状， 其他人症状或者不察觉要不就是不明显。  

此疫苗已经进入准临床试验， 在动物实验中抑制作用良好。  看人吧， 毕竟人与耗子太不同了

看来我们这些痛苦的都是明显和最不幸的。  
主保佑
迷糊


Vical Provides Allovectin® and Herpes Simplex Vaccine Updates at BIO International Convention 06/28/2011
Download this News Release  

WASHINGTON, June 28, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company is presenting updates on its Phase 3 Allovectin® immunotherapeutic for metastatic melanoma and its preclinical herpes simplex type 2 (HSV-2) vaccine at the BIO International Convention (Washington, DC – June 27-30).

Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development is presenting both updates in breakout sessions of the Innovations in Vaccines Track on Tuesday, June 28. The HSV-2 vaccine presentation is included in the "Therapeutic and Prophylactic Approaches for the Treatment of HSV-2 Infection" session scheduled for 10:00 a.m. EDT and the Allovectin® presentation is included in the "Therapeutic Cancer DNA Vaccines: Advances in Technologies, Advances in Clinical Success" session scheduled for 2:00 p.m. EDT.

Allovectin® Update

Allovectin® is a systemic immunotherapeutic with a unique mechanism of action that may be complementary to currently approved treatments. Allovectin® is delivered into a single tumor lesion, but elicits a T-cell immune response directed against similar tumor lesions throughout the body. Vical is currently conducting animal studies to evaluate the potential synergy of Allovectin® with an anti-CTLA-4 monoclonal antibody, which works by expanding the number of active T cells.

Earlier this month at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Vical presented statistical analyses of data from three previously completed clinical trials of Allovectin® in patients with metastatic melanoma, showing with strong positive correlation that responders lived significantly longer than nonresponders. In Vical's ongoing Phase 3 trial of Allovectin®, the primary endpoint is objective response rate at 24 weeks or more after randomization, and overall survival is a secondary endpoint.

The Phase 3 trial is evaluating Allovectin®compared with standard chemotherapy as a first-line therapy in patients with Stage III or IV recurrent metastatic melanoma. Vical completed enrollment in February 2010 of 390 chemo-naive patients randomized on a 2:1 basis for treatment with Allovectin® or chemotherapy (physician's choice of either dacarbazine or temozolomide).

Allovectin® has demonstrated an excellent safety profile in multiple clinical trials. In the high-dose Phase 2 trial, there were no grade 3 or grade 4 drug-related adverse events. Safety has been a hallmark of Allovectin® treatment, and side effects typically have been local and not significant.

The mechanism of action for Allovectin® is applicable to solid tumors other than melanoma, and Vical has conducted early-stage clinical trials of Allovectin® in patients with breast, prostate, colorectal or kidney cancer, chronic lymphocytic leukemia, or squamous cell cancer of the head and neck. AnGes MG, Inc., has licensed rights to commercialize Allovectin® in specified Asian countries, and is primarily interested in developing Allovectin® as a treatment for head and neck cancer, which presents a significant unmet medical need in Asia. Vical estimates that the worldwide market for Allovectin® as a treatment for metastatic melanoma could exceed $500 million annually, and applications for other types of cancer could further expand its total use.

HSV-2 Vaccine Update

Vical is collaborating with the University of Washington School of Medicine and the Sealy Center for Vaccine Development at the University of Texas Medical Branch under a previously disclosed grant on the preclinical development of a HSV-2 vaccine formulated with Vical's Vaxfectin® adjuvant. The initial focus will be for people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups as well as viral shedding and transmission.

Data being presented today from repeat studies confirmed that the company's Vaxfectin® adjuvant significantly improved vaccine effectiveness (p<0.05). Vical's therapeutic vaccine significantly reduced the recurrence of HSV-2 lesions in guinea pigs with latent infection (p<0.05). A related prophylactic vaccine protected mice against lethal HSV-2 challenge (p<0.0001), provided sterilizing immunity (p<0.05) and inhibited post-challenge viral shedding at the primary infection site (p<0.05) and viral load at the latent infection site (p=0.007).

HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes.Approximately one out of every six individuals in the United States and an estimated one out of every four worldwide is infected by HSV-2 before age 50. HSV-2 infections are persistent and result in periodic virus shedding. HSV-2 infection also significantly increases the risk of acquiring HIV-1. In the United States, at least 40 million people are infected with HSV-2, and approximately 1.6 million people are newly infected each year, with approximately 500,000 of those suffering from disease symptoms. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV.

There is currently no approved vaccine for HSV-2. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost over the years and potential for drug resistance highlight the need for safe, new approaches to reducing HSV-2 lesions, shedding, and transmission. Estimated direct costs of treating HSV-2 in the United States alone are close to $1 billion annually, primarily for drugs and outpatient medical care, plus additional indirect costs of more than $200 million.

英文好的一定要看这一段。  一个非常有头脑和思想的美国战友。  我受益匪浅。  我非常喜欢这种交流， 一个网站如果多了这种战友， 那这个网站也会有一种无形的吸引力。 有时打开我们的网， 除了希望不劳动而白白知道第二天一醒来最好有治愈的药外， 就是要死要活， 气场就不好。  所以说， 我希望我的楼是一个富有层次的交流楼， 而不是简单的索取答案或者等着我给你做义工的免费场。  迷糊没有给任何人打工， 我在这里希望与大家共进退， 共抗战！！

主保佑
迷糊


That's the interesting thing to me. A physical cure won't solve the psychological problems that H seems to bring out of the woodwork. There's no guarantee a cure will be found, even if something comes to market there's no guarantee that it will be effective for everyone. No medication works on 100% of people anyway so there will always be doubt. You will probably still have to disclose to potential partners.

Over and over again I read posts by people who say things like "I can't live with this virus" ( despite the fact that they are obviously living well enough to type), or " I used to have confidence and feel like a sexy person, now my life is over" which is absurd. Such a person was not really a confident person to begin with or they wouldn't say that. My point is that the negative effects are really all in your head, and the social burden is in society's collective head. A physical cure won't change that. It seems to me that instead of praying for a medical cure ( which will be a physical cure, not a magical vaccine that will erase the Stigma), one's energy is better spent rising to the occasion and growing as a person, training yourself to handle adversity with grace, developing real confidence and educating yourself and the people around you in order to reduce the Stigma.

Humans have lived with herpes since at least the ancient Greeks, it's part of the human condition. the Stigma is a silly recent phenomenon from the early 1980s concocted by a pharmaceutical company's marketing department to sell Zovirax. I imagine the ancient Greeks are laughing at our silliness and our sissiness.

最后一段话打动了我，是的，我觉得不要放在心上是最佳的心理疗法

那现在就是没有准备上市的新药物！哎.0...........不知道还要等多久！有新药物或疫苗！来根治这病！

那我跟的性伴侣都有带套了怎么还染上了呢:'( :'( :'(